Key result
A 52-year-old woman developed a large hemorrhagic pericardial effusion and cardiac tamponade requiring emergent pericardiocentesis one week following her second dose of the BNT162b2 COVID-19 vaccine.
Case Report (n=1)
No
This case highlights the rare but severe risk of hemorrhagic pericardial effusion and cardiac tamponade following mRNA-based COVID-19 vaccination, emphasizing the need for clinical vigilance in patients presenting with chest pain post-vaccination.
Answers are grounded in this paper and cite their sources.
Warrants vigilance for tamponade in post-mRNA vaccine chest pain; single case leaves open causality and incidence.
The introduction of mRNA-based COVID-19 vaccinations has been useful in decreasing risks of severe illness with COVID-19 infection. Cardiac tamponade is a rare cardiovascular emergency that has been observed following both mRNA-based COVID-19 vaccinations and COVID-19 infections. We report the first case of a hemorrhagic pericardial effusion with cardiac tamponade in a 52-year-old woman occurring one week following the second dose of the BNT162b2 (BioNTech/Pfizer) SARS-CoV-2 vaccination. The time sequence in this case report correlates with reports submitted to the Vaccine Adverse Event Reporting System (VAERS), which indicates that cases of pericarditis following mRNA vaccination most commonly occur within 1-2 weeks following the second dose of vaccination.
No takes yet. Share an insight, caveat, or question.
Nguyen et al. (2022) conducted a case report in Hemorrhagic pericardial effusion and cardiac tamponade (n=1). BNT162b2 (BioNTech/Pfizer) COVID-19 vaccine was evaluated on Development of hemorrhagic pericardial effusion and cardiac tamponade. A 52-year-old woman developed a large hemorrhagic pericardial effusion and cardiac tamponade requiring emergent pericardiocentesis one week following her second dose of the BNT162b2 COVID-19 vaccine.
Synapse has enriched 10 related papers. Consider them for comparative context: